Spectral MD - Initiation Note - JUL 22
Spectral MD is a specialist in predictive analytics for medical applications. It uses its proprietary camera to take multispectral pictures of wounds such as burns and diabetic foot ulcers and its proprietary AI algorithms to determine, on day-one and with accuracy levels far exceeding current standards, which parts of the injured tissue will heal using everyday care and which ones need immediate intervention, removing delays of up to 30 days for treatment decisions.SMD offers a disruptive technology to meet an unmet clinical need, at a reasonable cost, in massive and growing global healthcare markets that aren't strongly correlated with economic cycles or inflationary problems. It has excellent connections within those markets, and reports early excitement from physicians. It's also well protected by IP & data ownership, and has secured generous (non-dilutive, non-refundable) government R&D grants that should lead to large procurement contracts. It has favoured status with the FDA, faces no immediate competition, and has a clear route to short term (2023) commercialisation. The consensus target price is 160p, some 351% ahead of the current share price.
Capital Access Group advises companies on effective engagement with investors. Our experienced team offers market-leading access with hard-to-reach investors, including smaller institutions, pension funds and private client fund managers. These under-serviced investors are located not only in London but across the regions of the UK and Europe. We have an unrivalled knowledge of this extensive audience, to whom our published research is distributed, as well as to larger institutions. We offer this service as part of an integrated investor communications strategy to promote a company’s investment story.
Our clients, ranging from AIM to FTSE 100 companies, benefit from our professional, long-term relationships with investors. Not only do we identify and target investors, we contact them directly and relay their views back to clients with analysis, interpretation and advice. This ensures that our clients are in control of their investor engagement. The objective is to improve the reach and engagement with investors, which in turn strengthens the share price.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.